Indian-Origin Leadership Shines as Two Firms Make TIME’s 2025 Top 100 List

TIME magazine has included Vertex Pharmaceuticals and CRISPR Therapeutics in its 2025 list of the 100 Most Influential Companies in the World. The recognition highlights the remarkable contributions of these biotech firms under the leadership of Indian-American CEOs.

Vertex Pharmaceuticals, led by Reshma Kewalramani, was honored under the Impact Awards category for its groundbreaking drug research. The company developed Casgevy, the first CRISPR-based treatment approved by the FDA for sickle cell disease and beta thalassemia, as well as Journavx, the first non-opioid painkiller approved in over two decades. Vertex is also advancing a cell-based therapy for type 1 diabetes, and has expanded into kidney disease treatment through its $4.9 billion acquisition of Alpine Immune Sciences.

Meanwhile, CRISPR Therapeutics, headed by Samarth Kulkarni, was recognized under the Pioneers category. Co-developer of Casgevy, the company is now exploring CRISPR-based treatments for high cholesterol and lupus—both widespread conditions in urgent need of innovative therapies.

Both leaders emphasized their commitment to transformative science and improving patient outcomes. This recognition underscores their global significance in driving bold innovations in genetic medicine and beyond.